Using Fasudil Hydrochloride to treat gene-specific ovarian cancer
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
This study is testing if Fasudil Hydrochloride can help ovarian cancer patients with a specific genetic type feel better and improve their treatment results when added to their current chemotherapy.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Zhejiang Provincial People's Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06890858 on ClinicalTrials.gov |
What this trial studies
This clinical study investigates the effectiveness of Fasudil Hydrochloride in treating ovarian cancer patients with the A/A genotype. It aims to evaluate whether this treatment can improve patient outcomes by targeting the Rho signaling pathway, which is implicated in cancer cell proliferation and invasion. The study will enroll 20 patients who have shown disease stability or progression after platinum-based chemotherapy and have been confirmed to have the A/A genotype through genetic testing. The goal is to enhance the prognosis for these patients by combining Fasudil with their existing chemotherapy regimen.
Who should consider this trial
Good fit: Ideal candidates for this study are ovarian cancer patients with the A/A genotype who have experienced disease stability or progression after platinum-based chemotherapy.
Not a fit: Patients with hypotension, bleeding disorders, or abnormal liver function may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the prognosis for patients with gene-specific ovarian cancer.
How similar studies have performed: Preliminary studies have shown promise in using Fasudil for similar applications, but this specific approach is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients voluntarily participate in the study, sign informed consent forms, and have good compliance. 2. After platinum based chemotherapy at Zhejiang Provincial People's Hospital, the efficacy evaluation showed that ovarian cancer patients who achieved disease stability (SD) or disease progression (PD) twice were treated with Fasudil in combination with the original chemotherapy regimen, and were confirmed to have the A/A genotype through genetic testing. Exclusion Criteria: * 1.Accompanied by hypotension 2. Bleeding like cerebral hemorrhage 3. Patients with abnormal liver function
Where this trial is running
Hangzhou, Zhejiang
- Zhejiang Provincial People's Hospital — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Yang Liu, M.D.
- Email: yangliuqq2003@163.com
- Phone: 13666601475
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.